Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET

Scheffler M, Kobe C, Zander T, Nogova L, Kahraman D, Thomas RK, Neumaier B, Dietlein M, Wolf J

Journal: Lung Cancer, Vol 77, No 3, September 2012, doi: 10.1016/j.lungcan.2012.05.110
Veröffentlichung: September 2012